Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01954043




Registration number
NCT01954043
Ethics application status
Date submitted
26/09/2013
Date registered
1/10/2013
Date last updated
14/11/2017

Titles & IDs
Public title
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
Scientific title
An Open-label Study to Evaluate the Effects of a Potent CYP3A4 Inducer and the Effects of a pH Elevating Agent on the Repeat Dose Pharmacokinetics of Dabrafenib (GSK2118436) in Subjects With BRAF V600 Mutation Positive Tumors
Secondary ID [1] 0 0
200072
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cancer 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dabrafenib 150 mg twice a day (BID)
Treatment: Drugs - Rabeprazole 40 mg once daily (OD)
Treatment: Drugs - Rifampin 600 mg OD

Experimental: Arm A - Subjects will administer Dabrafenib from Day 1 to Day 15, Dabrafenib and Rabeprazole from Day 16 to Day 19, Dabrafenib and Rifampin from Day 20 to Day 29. The serial PK samples will be collected for 12 hours following dosing on Day 15 (Dabrafenib alone), Day 19 (Dabrafenib and Rabeprazole), and Day 29 (Dabrafenib and Rifampin).


Treatment: Drugs: Dabrafenib 150 mg twice a day (BID)
Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29

Treatment: Drugs: Rabeprazole 40 mg once daily (OD)
Rabeprazole dosed at 40mg each morning on Days 16 to 19

Treatment: Drugs: Rifampin 600 mg OD
Rifampin dosed at 600mg each morning on Days 20 to 29
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
PK assessment (Cmax) of Dabrafenib with and without Rabeprazole or Rifampin
Timepoint [1] 0 0
Day 15, 19 and Day 29
Primary outcome [2] 0 0
PK assessment (tmax) of Dabrafenib with and without Rabeprazole or Rifampin
Timepoint [2] 0 0
Day 15, 19 and Day 29
Primary outcome [3] 0 0
PK assessment (AUC[0-tau]) of Dabrafenib with and without Rabeprazole or Rifampin
Timepoint [3] 0 0
Day 15, 19 and Day 29
Secondary outcome [1] 0 0
PK assessment of Dabrafenib co administered with rabeprazole or rifampin
Timepoint [1] 0 0
Day 15, 19 and Day 29
Secondary outcome [2] 0 0
PK assessment (AUC[0-tau]) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib
Timepoint [2] 0 0
Day 15, 19 and Day 29
Secondary outcome [3] 0 0
PK assessment (Cmax and Ctau,) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib
Timepoint [3] 0 0
Day 15, 19 and Day 29
Secondary outcome [4] 0 0
PK assessment (tmax) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib
Timepoint [4] 0 0
Day 15, 19 and Day 29
Secondary outcome [5] 0 0
Ratio of metabolite to Dabrafenib
Timepoint [5] 0 0
Day 15, 19 and Day 29
Secondary outcome [6] 0 0
Safety and tolerability assessment to measure vital signs
Timepoint [6] 0 0
Day 15, 19 and Day 29
Secondary outcome [7] 0 0
Safety and tolerability assessment for 12-lead ECG
Timepoint [7] 0 0
From Screening up to follow up visit within 7-10 days of the last dose of study medication
Secondary outcome [8] 0 0
Safety and tolerability assessment for laboratory tests
Timepoint [8] 0 0
From Screening up to follow up visit within 7-10 days of the last dose of study medication
Secondary outcome [9] 0 0
Safety and tolerability assessment of dabrafenib in combination with rabeprazole or rifampin
Timepoint [9] 0 0
From Screening up to follow up visit within 7-10 days of the last dose of study medication
Secondary outcome [10] 0 0
Concentrations of Rabeprazole in the presence of Dabrafenib
Timepoint [10] 0 0
Predose, 1, 2, 3 and 12 hours postdose on Day 19
Secondary outcome [11] 0 0
Concentrations of Rifampin in the presence of Dabrafenib
Timepoint [11] 0 0
Predose, 1, 2, 3 and 12 hours postdose on Day 29

Eligibility
Key inclusion criteria
* Male or female at least 18 years of age at the time of signing the informed consent form.
* Provided signed written informed consent.
* Capable of compliance with the requirements and restrictions listed in the consent form.
* Body weight >=45 kilogram (kg) and a body mass index (BMI) >=19 Kilogram per meter squared (kg/m^2) and <40 kg/m^2 (inclusive).
* Able to swallow and retain oral medication.
* BRAF V600 mutation-positive tumor as confirmed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory or equivalent.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate baseline organ function defined in study protocol.
* Women of child-bearing potential must be willing to practice acceptable methods of birth control. Additionally, women of childbearing potential must have a negative serum pregnancy test within 14 days prior to the first dose of study medication.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* History of another malignancy with exceptions below, or any malignancy with confirmed activating RAS mutation. Exception: (a) Subjects who have been successfully treated and are disease-free for 5 years, (b) a history of completely resected non-melanoma skin cancer, (c) successfully treated in situ carcinoma, (d) CLL in stable remission, or (e) indolent prostate cancer (definition: clinical stage T1 or T2a, Gleason score <=6, and PSA <10 nanogram per milliliter [ng/mL]) requiring no or only anti-hormonal therapy, are eligible.
* Cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or major surgery) or investigational anti-cancer drugs within the last 3 weeks, or chemotherapy without delayed toxicity within the last 2 weeks, preceding the first dose of dabrafenib.
* Unresolved toxicity greater than Grade 2 from previous anti-cancer therapy except alopecia.
* Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject's safety, obtaining informed consent or compliance to the study procedures.
* Current use of therapeutic warfarin.
* Any prohibited medication(s) or herbal preparation as described in study protocol or requires any of these medications during the study.
* Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to dabrafenib, rabeprazole and rifampin, or excipients that contraindicates their participation.
* Pregnant or nursing females.
* A history or evidence of cardiovascular risk including any of the following: a QT interval corrected for heart rate using the Bazett's formula (QTcB) >=480 milliseconds (msec); a history or evidence of current clinically significant uncontrolled arrhythmias; a history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization; a history or evidence of current >=Class II congestive heart failure (CHF) as defined by the New York Heart Association (NYHA) guidelines; Abnormal cardiac valve morphology (>=grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.
* Presence of active gastrointestinal (GI) disease or other condition (e.g., small bowel or large bowel resection) that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK Medical Monitor.
* A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus infection.
* Subjects with brain metastases are excluded if their brain metastases are: Symptomatic, Treated (surgery, radiation therapy) but not clinically and radiographically stable one month after local therapy, or asymptomatic and untreated but >1 centimeter (cm) in the longest dimension. Subjects with small (<=1 cm in the longest dimension), asymptomatic brain metastases that do not need immediate local therapy can be enrolled. Subjects on a stable dose of corticosteroids for >1 month, or those who have been off corticosteroids for at least 2 weeks can be enrolled. Subjects must also be off of enzyme-inducing anticonvulsants for more than 4 weeks.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
20/12/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
29/02/2016
Sample size
Target
Accrual to date
Final
23
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
GSK Investigational Site - Heidelberg
Recruitment hospital [2] 0 0
GSK Investigational Site - Melbourne
Recruitment postcode(s) [1] 0 0
3084 - Heidelberg
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Texas
Country [3] 0 0
United States of America
State/province [3] 0 0
Washington
Country [4] 0 0
United Kingdom
State/province [4] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT01954043